Proteocyte AI

What if we could identify high-risk lesions at the earliest possible stage?

In our recent webinar, we explored how earlier risk identification—supported by real patient examples—can change the trajectory of care.

When clinicians have clearer insight into which lesions are more likely to progress, they can act sooner—potentially improving outcomes while reducing unnecessary interventions.

STRATICYTE® helps make this possible by providing an objective, personalized risk assessment to guide decision-making.

Watch the full webinar :
👉 https://vimeo.com/1166776243/70fe5d4b60


Nova Scotia Dental Association Ontario Dental Association Ontario Society of Oral and Maxillofacial Surgery The Terry Fox Foundation The Princess Margaret Cancer Foundation

What is the STRATICYTE® test—and how does it help?

STRATICYTE® uses biomarker analysis, digital pathology, and AI-driven algorithms to go beyond traditional histology—delivering an objective, personalized 5-year oral cancer risk score.

Instead of relying on subjective grading alone, clinicians gain clearer insight into which lesions may require closer monitoring or earlier intervention.

It’s a new layer of intelligence in oral cancer risk assessment—supporting more informed, confident decisions.

Watch the full webinar:
👉 https://vimeo.com/1166776243/70fe5d4b60


Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society